Purpose: Anaemia is quite common and yet, independent poor prognostic factor for oncology patients. Among haematological tests, reticulocyte counts are standard tests to determine different types and treatments of anaemia along with the functionality of bone marrow. Various routine and research reticulocyte parameters are generated by Mindray BC-6800. The aim and objective of this study are to analyze automated reticulocyte parameters used in routine and research in anaemic and non-anaemic oncology patients. Our hypothesis is to find whether reticulocyte parameters should be a part of a complete blood count report in oncology patients to guide clinicians for further evaluation or management. Methods: A total of 272 routine samples were obtained randomly over three months, and run through an analyzer to evaluate reticulocyte parameters. Parameters obtained include RET%, ARC, IRF, HFR, MFR, LFR, RetHe, RPI, MCHr and MRV. Result: Reticulocyte parameters were generated by BC-6800 for 272 samples, from which 152 patients were anaemic while 120 patients were non-anaemic. Abnormal values for routine and research parameters like RET%, ARC, IRF, HFR, MFR, LFR, RetHe, RPI, MCHr and MRV were 41.91%, 59.93%, 19.85%, 29.04%, 3.68%, 27.94%, 56.99%, 4.78%, 63.97% and 55.51%, respectively. Conclusion: The present study showed significant abnormal results of reticulocyte parameters oncology patients. It is used for haematology laboratories to contemplate reticulocyte parameters as a part of complete blood count to guide clinicians for the management of cancer patients with the addition of interpretative comments to emphasize erythropoietic activity to increase ac ceptability and the efficacy of anti-cancer treatment and may also find some impact on prognosis.